- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04565028
Functional Outcomes of Cannabis Use (FOCUS) in Veterans With Posttraumatic Stress Disorder (FOCUS)
December 19, 2023 updated by: VA Office of Research and Development
Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that affects 20%-30% of U.S. Veterans.
PTSD is strongly associated with increased risk for substance abuse comorbidity, including cannabis use disorder.
Multiple states now include PTSD as a condition for which patients can be legally prescribed medical marijuana, despite the fact that there has not been a single large-scale randomized clinical trial demonstrating the efficacy of cannabis to treat PTSD to date.
The overall objective of the current proposal is to study the impact of reduced cannabis use on functioning among Veterans with PTSD.
The investigators will evaluate the relationship between cannabis use and daily functioning among cannabis users and heavy cannabis users.
The central hypothesis is that reductions in cannabis use will lead to positive changes in the functional outcomes of Veterans.
The rationale for this research is that it will provide the first and only real-time data concerning the impact of reduced cannabis use on daily functioning among Veterans with PTSD.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that affects 20%-30% of U.S. Veterans.
PTSD is strongly associated with increased risk for substance abuse comorbidity, including cannabis use disorder; however, multiple states now include PTSD as a condition for which patients can be legally prescribed medical marijuana, despite the fact that there has not been a single large-scale randomized clinical trial demonstrating the efficacy of cannabis to treat PTSD to date.
The overall objective of the current proposal is to prospectively study the impact of reduced cannabis use on psychosocial functioning among Veterans with PTSD.
To do so, the investigators will first use ecological momentary assessment (EMA) methods to evaluate the relationship between cannabis use and daily functioning among Veterans with PTSD.
Next, the investigators will use mobile contingency management (CM) and EMA to assess the impact of reduced cannabis use on daily functioning among Veterans with PTSD who are heavy cannabis users.
The central hypothesis is that reductions in cannabis use will lead to positive changes in the functional outcomes of Veterans.
The rationale for this research is that it will provide the first and only real-time data concerning the impact of reduced cannabis use on daily functioning among Veterans with PTSD.
As a result, this innovative and timely project has the potential to significantly advance VHA healthcare and will directly inform the ongoing national debate concerning the impact of cannabis use on the long-term functional recovery of Veterans with PTSD.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jean C Beckham, PhD
- Phone Number: 7973 (919) 286-0411
- Email: jean.beckham@va.gov
Study Contact Backup
- Name: Angela C Kirby, MS
- Phone Number: 7456 (919) 286-0411
- Email: angela.kirby@va.gov
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705-3875
- Recruiting
- Durham VA Medical Center, Durham, NC
-
Contact:
- Jean C Beckham, PhD
- Phone Number: 7973 (919) 286-0411
- Email: jean.beckham@va.gov
-
Contact:
- Angela C Kirby, MS
- Phone Number: 7456 919-286-0411
- Email: angela.kirby@va.gov
-
Principal Investigator:
- Jean C Beckham, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Veteran status
- Ability to speak and write fluent English
- Current PTSD diagnosis
- Use of cannabis on 13+ days in the past month (i.e., use on 3+ days per week)
Exclusion Criteria:
Participants will be excluded if they:
- Have experienced a change in their psychiatric medication regimen during the past month (e.g., a new medication has been prescribed or the dose of an existing medication has been changed), or expect to experience a such a change during the course of the study
- Are receiving non-study CUD treatment
- Meet diagnostic criteria for bipolar disorder or schizophrenia (note that the SCID-5 (First et al., 2015) will be used to diagnoses these and other disorders)
- Become imprisoned
- Become hospitalized for psychiatric reasons
- Report imminent risk for suicide or homicide
- Meet current criteria for a substance use disorder other than cannabis use disorder or tobacco
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Contingency Management (CM)
Mobile contingency management (CM) will be used to promote reductions in cannabis use among Veterans with PTSD who are heavy cannabis users.
CM is an intensive behavioral therapy in which participants are paid to reduce substance use.
|
Contingency management is an intensive behavioral therapy in which participants are paid to reduce substance use.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in functional impairment as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS)
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Functional impairment will be measured by the simple score on the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS).
This measure has a scoring range of 0 to 144, with lower scores indicating lower functional impairment.
|
Baseline and post-treatment (approximately six weeks)
|
Change in functional impairment as measured by the Inventory of Psychosocial Functioning (IPF)
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Functional impairment will be measured by the Inventory of Psychosocial Functioning (IPF).
This measure has a scoring range of 0 to 480, with lower scores indicating higher functional impairment.
|
Baseline and post-treatment (approximately six weeks)
|
Change in psychiatric distress
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Psychiatric distress will be measured by the 90-item Symptom Checklist (SCL-90).
This measure has a scoring range of 0 to 360, with lower scores indicating lower distress related to mental health.
|
Baseline and post-treatment (approximately six weeks)
|
Change in quality of life, as measured by the WHOQOL-BREF
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Quality of life will be measured with the World Health Organization Quality of Life Brief (WHOQOL-BREF).
The measure has a scoring range of 0 to 100, with higher scores denoting a higher quality of life.
|
Baseline and post-treatment (approximately six weeks)
|
Change in quality of life, as measured by the Quality of Life Scale
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Quality of life will be measured with the 16-item Quality of Life Scale.
The measure has a scoring range of 6 to 112, with higher scores denoting a higher quality of life.
|
Baseline and post-treatment (approximately six weeks)
|
Change in number of days of drugged driving as measured by timeline follow-back
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Number of days of drugged driving in the past month will be self-reported by participants using a Timeline Follow-Back Interview.
|
Baseline and post-treatment (approximately six weeks)
|
Change in cannabis use
Time Frame: Baseline and post-treatment (approximately six weeks)
|
Cannabis use, as measured in milligrams, will be measured by taking the product of number of days used and amount used per day in the previous week.
|
Baseline and post-treatment (approximately six weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jean C Beckham, PhD, Durham VA Medical Center, Durham, NC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 26, 2022
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
September 18, 2020
First Submitted That Met QC Criteria
September 24, 2020
First Posted (Actual)
September 25, 2020
Study Record Updates
Last Update Posted (Actual)
December 26, 2023
Last Update Submitted That Met QC Criteria
December 19, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D3276-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The investigators do not plan to attend individual participant data.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on Contingency Management (CM)
-
NYU Langone HealthNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Oregon Social Learning CenterActive, not recruiting
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)CompletedAdolescent Substance UseUnited States
-
UConn HealthNational Institute of Mental Health (NIMH)Completed
-
Yale UniversityNational Cancer Institute (NCI)Completed
-
Oregon Health and Science UniversityOregon Health Authority; Comagine HealthRecruitingMethamphetamine AbuseUnited States
-
Washington State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompleted
-
University of OklahomaM.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Florida and other collaboratorsRecruiting
-
Parnassia Addiction Research CentreAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Leiden University... and other collaboratorsNot yet recruitingCannabis Use Disorder